UK's NICE recommends against NHS funding for Amgen's lung cancer drug Lumakras, citing cost-effectiveness well above its threshold.
The UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients.
In draft guidance released …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Two breakthrough Alzheimer's drugs cost too much and have too little benefit for NHS use, review finds.
Eli Lilly calls on Britain’s health service to pay higher prices for medicines
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Medicines watchdog approves two treatments for patients with spinal muscular atrophy
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head…
The claims from pharmaceutical giant Novartis comes amid a row over drug pricing deals.
